Calliditas: A SEK 208 cash bid from listed Asahi Kesei - Redeye

The bid is supported by 44.6% of shareholders, representing a bid premium of 74% compared with yesterday’s closing price. Listed Asahi Kesei has a private pharma business with a presence that is, in our view, well-placed to secure synergies by acquiring Calliditas. We regard the bid as well-timed and hardly surprising after extending the Tarpeyo patent support. In our view, the bid level does not rule out the prospects of a positive bid revision or the prospects of a competing bid.

Länk till analysen i sin helhet: https://www.redeye.se/research/1012209/calliditas-a-sek-208-cash-bid-from-listed-asahi-kesei?utm_source=finwire&utm_medium=RSS